A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.	B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease	Recruiting	Phase 1	2026-08-17		NCT06927466

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.	2

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital of Shanghai	Shanghai	China	4
Children's Hospital of Soochow University	Suzhou	China	7
Jiangxi Province pediatric hospital	Nanchang	China	1
Peking University People's Hospital	Beijing	China	68
Shanghai Children's Medical Center	Shanghai	China	9
The Affiliated Hospital of Xuzhou Medical University	Xuzhou	China	21
The First Affiliated Hospital of Nanchang University	Nanchang	China	55
Tongji Hospital	Wuhan	China	5